When microbial drug metabolism becomes a drug disposition variable.

Microbial transformation of drugs is experimentally established, but no agreed method determines when a detected pathway materially contributes to drug disposition. This minireview proposes a 5-gate framework for evaluating microbial metabolism as a source of drug-disposition variability. Evaluation begins by asking whether drug-related material reaches a microbial compartment, whether a defined drug-specific problem exists, and whether confirmation could change a development or therapeutic decision. Candidates then require demonstration of a defined microbial function, confirmation of an in vivo drug-specific consequence, comparison of effect magnitude with a prespecified pharmacologic benchmark, and evidence that the microbial measure improves prediction or decision-making beyond established covariates. The benchmark serves as the drug-specific denominator for interpreting microbial effect size. Route and formulation determine substrate access, sampling compartment, assay selection, and the relevant disposition endpoint. Transformation catalogs and genome-scale community models can prioritize pathways and estimate population heterogeneity, but predicted capacity is not equivalent to expressed activity, realized flux, or altered human exposure. A worked digoxin example compares the maximum reported increase of approximately 2-fold in serum concentration after suppression of microbial inactivation with recognized digoxin drug interactions. The framework complements existing microbiome tools by defining when mechanistic findings justify targeted drug-metabolism, pharmacokinetic, or drug-development evaluation. Microbial metabolism becomes a drug-disposition variable when measured function produces a reproducible, quantitatively material effect on drug behavior and provides information beyond established covariates. SIGNIFICANCE STATEMENT: Microbial biotransformation is increasingly detectable, but detection alone does not establish that microbial activity materially alters drug disposition. This minireview proposes a 5-gate framework that connects microbial-compartment exposure and demonstrated function to an in vivo drug-specific consequence, compares effect magnitude with a prespecified pharmacologic benchmark that serves as the drug-specific denominator, and requires incremental predictive or decision value before microbial measures advance beyond targeted drug-development evaluation.